

Michael B. Lynch (SBN 219214)  
THE MICHAEL BRAY LYNCH FIRM  
127 West Fairbanks Avenue, Suite 528  
Winter Park, Florida 32789  
Telephone: (877) 513-9517  
Facsimile: (321) 972-3568  
Email: [michaelblynch@me.com](mailto:michaelblynch@me.com)

Jessica C. Foster (SBN 228796)  
MILSTEIN ADELMAN JACKSON FAIRCHILD & WADE, LLP  
10250 Constellation Blvd., 14th Floor  
Los Angeles, CA 90067  
Telephone: (310) 396-9600  
Facsimile: (310) 396-9635  
Email: [jfoster@majfw.com](mailto:jfoster@majfw.com)

UNITED STATES DISTRICT COURT  
NORTHERN DISTRICT OF CALIFORNIA  
(SAN FRANCISCO DIVISION)

HARVEY ELLENTHAL

Plaintiff,

vs.

PFIZER, INC.;

Defendant.

Case No.: \_\_\_\_\_

**COMPLAINT FOR DAMAGES**

- 1. Unfair and Deceptive Trade Practices (Unfairness)**
  - 2. Unfair and Deceptive Trade Practices (Fraud)**
  - 3. Unfair and Deceptive Trade Practices (Unlawfulness)**
  - 4. Strict Liability – Defective Design**
  - 5. Strict Liability – Failure to Warn**
  - 6. Failure to Test**
  - 7. Negligence**
  - 8. Gross Negligence**
  - 9. Negligence Per Se**
  - 10. Breach of Express Warranty**
  - 11. Breach of Implied Warranty**
  - 12. Fraudulent Misrepresentation and Concealment**
  - 13. Negligent Misrepresentation and Concealment**
  - 14. Fraud and Deceit**
  - 15. Willful, Wanton, and Malicious Conduct**
  - 16. Unjust Enrichment**
- DEMAND FOR JURY TRIAL**

Plaintiff, HARVEY ELLENTHAL, individually alleges:

**BACKGROUND**

1 This is an action for personal injuries and damages suffered by Plaintiff Harvey  
2 Ellenthal (“Plaintiff”) as a direct and proximate result of Pfizer, Inc.’s (“Pfizer”) negligent and  
3 wrongful conduct in connection with the design, development, manufacture, testing, packaging,  
4 promoting, marketing, distribution, labeling, and/or sale of sildenafil citrate tablets sold under  
5 the brand name Viagra® (“Viagra”).

6 **JURISDICTION AND VENUE**

7 1. This Court has jurisdiction over this action pursuant to 28 U.S.C. § 1332,  
8 because the amount in controversy exceeds \$75,000.00, exclusive of interest and costs, and  
9 because Pfizer is a citizen of a state other than the state in which Plaintiff is a citizen.

10 2. The Parties conferred regarding jurisdiction and venue before filing in the  
11 Northern District of California.

12 3. On December 11, 2015, Plaintiff’s counsel in this and in other similar cases  
13 pending in federal courts around the country filed a petition with the Judicial Panel on  
14 Multidistrict Litigation (JPML) seeking coordination of all such matters before this Honorable  
15 Court in the Northern District of California. *See In re Viagra Products Liability Litigation*,  
16 MDL No. 2691. The petition is fully briefed and unopposed by the Defendant and all other  
17 interested parties. The JPML heard oral arguments on March 31, 2016.

18 4. Related Viagra actions are pending in this and other federal judicial districts  
19 across the country. The parties have stipulated to stay all activity until the JPML issues an order  
20 ruling Plaintiffs’ petition seeking coordination. In view of this pretrial cooperation, Plaintiff is  
21 filing this Complaint in the Northern District of California. Plaintiff reserves the right to assert  
22 all of his legal claims under California substantive law in that Plaintiff resides in the County of  
23 Broward County, State of Florida (hereinafter “Plaintiff’s Home Forum”). For purposes of  
24 remand and trial, venue is proper in the Plaintiff’s Home Forum, in Florida.

25 5. Plaintiff’s Home Forum is the United States District Court for the Southern  
26 District of Florida. Plaintiff is domiciled in Florida. Plaintiff was prescribed Viagra in Florida,  
27 he was exposed to Viagra in Florida, and he sustained his injuries in Florida.



1           13.     Erectile dysfunction is the medical designation for a condition in which a man  
2 cannot achieve or maintain an erection sufficient for satisfactory sexual activity. Since  
3 achieving and/or maintaining an erection involves the brain, nerves, hormones, and blood  
4 vessels, any condition that interferes with any of these functional areas of the body may be  
5 causally related to an individual's erectile dysfunction. These problems become more common  
6 with age, but erectile dysfunction can affect a man at any age.

7           14.     Viagra treats erectile dysfunction by inhibiting the secretion of  
8 phosphodiesterase type 5 ("PDE5"), an enzyme responsible for the degradation of cyclic  
9 guanosine monophosphate ("cGMP"). When the cGMP is not degraded by the PDE5, smooth  
10 muscles in the corpus cavernosum relax; this, in turn, permits an inflow of blood to the corpus  
11 cavernosum, creating an erection.

12           15.     The National Institutes of Health estimate that erectile dysfunction affects as  
13 many as thirty million men in the United States.<sup>1</sup>

14     B.     Prevalence of Viagra in Market

15           16.     In its 2013 Annual Report, Pfizer states that it accumulated revenue exceeding  
16 \$1,800,000,000 from worldwide sales of Viagra. This statistic is particularly significant in light  
17 of the fact that Pfizer lost exclusivity of Viagra throughout Europe in 2013, which in itself led to  
18 a drop in profits from the previous calendar year.

19           17.     Viagra holds approximately 45% of the United States market share for erectile  
20 dysfunction medications.<sup>2</sup>

21           18.     Pfizer estimates that Viagra has been prescribed to more than 35 million men  
22 worldwide.<sup>3</sup>

23           19.     In 2012 alone, physicians wrote approximately eight million prescriptions for  
24 Viagra.<sup>4</sup>

25 \_\_\_\_\_  
26 <sup>1</sup> NIH Consensus Development Panel on Impotence (July 7, 1993).

27 <sup>2</sup> Jacque Wilson, *Viagra: The Little Blue Pill That Could*, CNN, Mar. 27, 2013, available at:  
<http://www.cnn.com/2013/03/27/health/viagra-anniversary-timeline/index.html>.

28 <sup>3</sup> Hilary Stout, *Viagra: The Thrill That Was*, N.Y. TIMES, June 5, 2011, available at:  
<http://query.nytimes.com/gst/fullpage.html?res=9B06E3DF173FF936A35755C0A9679D8B63>.

<sup>4</sup> Wilson, *supra* note 4.

1 C. Pfizer's Knowledge of Defect

2 20. In a 1997 FDA Carcinogenicity Assessment Committee Report, rats were given  
3 60 mg/kg per day of sildenafil, a dose less than the maximum dose approved for human  
4 consumption, and an increased proliferation in thyroid follicular cells was observed.<sup>5</sup> Evidence  
5 from a separate study suggested an alternative explanation of increased proliferation, however,  
6 this study was conducted with a different dosage and did not apply the 60 mg/kg dosage given  
7 to rats that experienced a proliferation of thyroid follicular cells.

8 21. In the same FDA report, mice studies were not carried to completion due to  
9 increased mortality.<sup>6</sup> Groups receiving a 30 mg/kg dose of sildenafil were near or below 20  
10 percent survival and were terminated after 13-15 months of treatment. Groups receiving a 10  
11 mg/kg dose of sildenafil were near 20 percent survival and were terminated after 19-22 months  
12 of treatment.

13 22. Unbeknownst to most Viagra users, recent studies have shown that the cellular  
14 activity providing the mechanism of action for Viagra may also be associated with the  
15 development and/or exacerbation of melanoma.

16 23. The American Cancer Society states that melanoma is "the most serious type of  
17 skin cancer."<sup>7</sup>

18 24. According to the National Cancer Institute, part of the National Institutes of  
19 Health, melanoma is more likely than other skin cancers to spread to other parts of the body,  
20 thereby causing further tissue damage and complicating the potential for effective treatment and  
21 eradication of the cancerous cells.<sup>8</sup>

22 25. Several studies have linked the mechanism of action for Viagra to cell mutation  
23 cultivating melanomagenesis, or the creation of melanocytes which develop into melanoma.

24 \_\_\_\_\_  
25 <sup>5</sup> *Carcinogenicity Assessment Report and FDA-CDER Rodent Carcinogenicity Database*  
26 *Factsheet*, NDA #20-895 (1997), available at:  
[http://www.accessdata.fda.gov/drugsatfda\\_docs/nda/98/viagra/carcin\\_rep.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/viagra/carcin_rep.pdf).

27 <sup>6</sup> *Id.*

28 <sup>7</sup> American Cancer Society, *Skin Cancer Facts*, last revised March 19, 2014, available at:  
<http://www.cancer.org/cancer/cancercauses/sunanduvexposure/skin-cancer-facts>.

<sup>8</sup> National Cancer Institute, *Types of Skin Cancer*, last updated Jan. 11, 2011, available at:  
<http://www.cancer.gov/cancertopics/wyntk/skin/page4>.

1           26. A study published in 2011 found that treatment with Viagra can promote  
2 melanoma cell invasion.<sup>9</sup> Specifically, by inhibiting PDE5, Viagra mimics an effect of gene  
3 activation and therefore may potentially function as a trigger for the creation of melanoma cells.

4           27. A 2012 study published in the Journal of Cell Biochemistry also found that  
5 PDE5 inhibitors were shown to promote melanin synthesis,<sup>10</sup> which may exacerbate melanoma  
6 development.<sup>11</sup>

7           28. On April 7, 2014, an original study (“the JAMA study”) was published on the  
8 website for the *Journal of the American Medical Association Internal Medicine* which, in light  
9 of the previous studies, sought to examine the direct relationship between sildenafil use and  
10 melanoma development in men in the United States.<sup>12</sup> The JAMA study was published in the  
11 journal’s June 2014 edition.

12           29. Among 25,848 participants, the JAMA study reported that recent sildenafil users  
13 at baseline had a significantly elevated risk of invasive melanoma, with a “hazard ratio” of 1.84;  
14 in other words, the study participants who had recently used sildenafil exhibited an 84%  
15 increase in risk of developing or encouraging invasive melanoma.<sup>13</sup>

16 D. Consumer Expectations

17           30. Since Viagra’s FDA approval in 1998, Pfizer has engaged in a continuous,  
18 expensive, and aggressive advertising campaign to market Viagra to men worldwide as a  
19 symbol of regaining and enhancing one’s virility.

20           31. Viagra has engaged in increasingly aggressive marketing techniques and  
21 strategies to promote the use of Viagra in the face of increasing pharmaceutical competition. By  
22 means of demonstration, a 2004 article in The Chicago Tribune cited industry reports stating

23 \_\_\_\_\_  
24 <sup>9</sup> I. Arozarena, et al., *Oncogenic BRAF Induces Melanoma Cell Invasion by Downregulating  
The cGMP-Specific Phosphodiesterase PDE5A*, 19 CANCER CELL 45 (2011).

25 <sup>10</sup> X Zhang, et al., *PDE5 Inhibitor Promotes Melanin Synthesis Through the PKG Pathway in  
B16 Melanoma Cells*, 113 J. CELL BIOCHEM. 2738 (2012).

26 <sup>11</sup> F.P. Noonan, et al., *Melanoma Induction by Ultraviolet A But Not Ultraviolet B Radiation  
Requires Melanin Pigment*, 3 NATURE COMMUNICATIONS 884 (2012).

27 <sup>12</sup> Wen-Qing Li, Abrar A. Qureshi, Kathleen C. Robinson, & Jiali Han, *Sildenafil Use and  
Increased Risk of Incident Melanoma in U.S. Men: A Prospective Cohort Study*, 174 JAMA  
28 INTERNAL MEDICINE 964 (2014).

<sup>13</sup> *Id.*

1 that Viagra spent “tens of millions of dollars each month on direct-to-consumer advertising [  
2 ].”<sup>14</sup>

3 32. Pfizer has also been criticized by regulators, physicians and consumer groups for  
4 its attempts to target younger men in its advertising. Doctors and federal regulators stated that  
5 “such ads sen[t] a confusing message to patients who might really benefit from the drug.”<sup>15</sup>

6 33. While designing and formulating Viagra, Pfizer discovered or should have  
7 discovered that the drug’s mechanism of action, the inhibition of PDE5, also presented a  
8 significant risk of exacerbating melanoma.

9 34. Despite these significant findings, Pfizer has made no efforts in its ubiquitous  
10 Viagra advertisements to warn users about the potential risk of developing melanoma that has  
11 been scientifically linked to its drug.

12 35. Members of the general public had no plausible means through which they could  
13 have discovered the significant risk of melanomagenesis associated with PDE5 inhibition.

14 36. Prescribing physicians would not have had the same level of access to the  
15 research and development conducted by Pfizer prior to its decision to manufacture Viagra for  
16 general public use.

17 37. Pfizer failed to communicate to the general public that the inhibition of PDE5  
18 inherently necessary to the efficacy of Viagra would also present a significant risk of one’s  
19 development or exacerbation of cancerous cells.

20 38. For example, no individual prescribed to use Viagra would believe or be  
21 expected to know that his use of Viagra would expose him to an increased risk of developing  
22 melanoma or exacerbating the growth of melanocytes already present in his body.

23 39. Pfizer expected or should have expected individuals who suffered from erectile  
24 dysfunction to ingest Viagra as a means to treat their condition.

25 \_\_\_\_\_  
26 <sup>14</sup> Bruce Japsen, *Viagra’s 2 Rivals Grab Market Share In A Year*, CHICAGO TRIBUNE, Sept. 23,  
27 2004, available at [http://articles.chicagotribune.com/2004-09-23/business/0409230283\\_1\\_viagra-erectile-levitra](http://articles.chicagotribune.com/2004-09-23/business/0409230283_1_viagra-erectile-levitra).

28 <sup>15</sup> Bruce Japsen, *Toned-Down Advertising Credited for Viagra Gains*, CHICAGO TRIBUNE, Feb.  
8, 2007, available at [http://articles.chicagotribune.com/2007-02-08/business/0702080063\\_1\\_viagra-erectile-pfizer-spokesman](http://articles.chicagotribune.com/2007-02-08/business/0702080063_1_viagra-erectile-pfizer-spokesman).

1 40. Pfizer expected or should have expected physicians treating erectile dysfunction  
2 to prescribe Viagra as a means to treat the condition.

3 41. The risk presented by ingesting Viagra would be present from the moment of  
4 manufacture; that is, the user would not need to change or alter the drug itself or the means by  
5 which it was ingested in order for the drug to carry the same risk of harm as described herein.

6 E. Risks and Benefits of Viagra Use

7 42. At all times relevant hereto, Viagra was useful to some members of the  
8 population; namely, men diagnosed with erectile dysfunction.

9 43. Erectile dysfunction is not fatal, nor does it present any related symptoms or  
10 characteristics harmful to one's physical health; however, it did provide the benefit of allowing  
11 men with erectile dysfunction to achieve and maintain an erection.

12 44. Viagra also encourages the development of melanoma in the body of a user,  
13 thereby placing them at a significant health risk.

14 45. Pfizer manufactured, marketed and sold Viagra as a PDE5 inhibitor; however,  
15 the mechanism of action that made the drug effective in treating erectile dysfunction  
16 simultaneously enhanced the risk of the user developing melanoma.

17 46. At the time Viagra was formulated and manufactured, Pfizer knew or should  
18 have known that the drug posed a significantly heightened risk to users, specifically through the  
19 increased likelihood that those users would develop melanoma because of the chemical  
20 reactions inherent to the drug's functioning.

21 47. Through the testing and formulating of Viagra, and before the initiation of the  
22 drug's mass manufacture, Pfizer knew or should have known in the exercise of ordinary care  
23 that the chemical reactions inherent to Viagra's mechanism of action would present a cancer-  
24 related health hazard to potential future users.

25 48. The risk presented by the use of Viagra through PDE5 inhibition – a  
26 characteristic inherent to the drug's potential efficacy – was unquestionably far more significant  
27 than the benefit provided to its users.

28



1 49. Because the risk of using Viagra so greatly outweighs the benefits of such use,  
2 the drug presents an unreasonably dangerous risk when used in its intended condition.

3 F. Facts Regarding Plaintiff

4 50. Plaintiff began pharmaceutical treatment for erectile dysfunction in November of  
5 1999, when his physician, Dr. Gerald N. Halpern, prescribed Viagra.

6 51. Plaintiff continued to fill his Viagra prescriptions from Dr. Gerald N. Halpern  
7 and take the drug regularly until at least September 17, 2001.

8 52. On August 24, 2012, Dr. Pamela Rousseau of Skin Cancer and Associates  
9 conducted a biopsy of a skin lesion on Plaintiff's left chest. The biopsied skin was diagnosed as  
10 malignant melanoma in situ.

11 53. On September 20, 2012, Dr. Pamela Rousseau conducted a re-excision of  
12 Plaintiff's left chest melanoma.

13 54. Since first being diagnosed with melanoma, Plaintiff has had to remain vigilant  
14 in monitoring his skin for lesions.

15 55. As a direct, proximate, and legal result of Pfizer's negligence and wrongful  
16 conduct, and the unreasonably dangerous and defective characteristics of the drug Viagra,  
17 Plaintiff suffered severe and permanent physical and emotional injuries. His physical injuries  
18 have included melanoma as well as the multiple surgeries necessitated by his skin cancer  
19 diagnosis. Plaintiff has endured not only physical pain and suffering but also economic loss,  
20 including significant expenses for medical care and treatment. Because of the nature of his  
21 diagnosis, he will certainly continue to incur such medical expenses in the future. As a result of  
22 these damages, Plaintiff seeks actual and punitive damages from Pfizer.

23 G. Summary

24 56. At all times relevant to this lawsuit, Pfizer engaged in the business of  
25 researching, licensing, designing, formulating, compounding, testing, manufacturing,  
26 producing, processing, assembling, inspecting, distributing, marketing, labeling, promoting,  
27 packaging and/or advertising for sale or selling the prescription drug Viagra in California,  
28 Plaintiff's Home Forum, and throughout the United States.



(Unfairness)

1           63. Plaintiff adopts and incorporates all preceding paragraphs as if stated fully  
2 herein.

3           64. California Business & Professions Code Section 17200 (“Unfair Competition  
4 Law” or “UCL”) and applicable statutes and laws of Plaintiff’s Home Forum preclude unfair  
5 competition: *i.e.*, the employment of any unlawful, unfair or fraudulent business acts or  
6 practices; and, any unfair, deceptive, untrue or misleading advertising (Cal. Bus. & Prof. Code  
7 Section 17500). This prohibition extends to any act, omission, or conduct affecting the rights of  
8 consumers.

9           65. Pfizer has designed and continues to design, manufacture, market, sell, and place  
10 into the stream of commerce the Viagra purchased and used in California, Plaintiff’s Home  
11 Forum, and throughout the United States. Pfizer has failed and continues to fail to disclose and  
12 conceal the serious safety hazard posed by the design of Viagra—it does not warn Plaintiff or  
13 his physicians of the increased risk of developing melanoma as a result of using Viagra, and  
14 should not be purchased or used for that purpose.

15           66. Pfizer has been and remains obligated to disclose this material safety hazard  
16 because reasonable consumers expect Viagra to perform its only intended and reasonably  
17 expected function and purpose of allowing a user to achieve and maintain an erection. In failing  
18 to disclose this critical safety hazard, known to Pfizer but not to reasonable consumers like  
19 Plaintiff and his physicians, Pfizer engaged in and continues to engage in unfair conduct under  
20 Cal. Bus. & Prof. Code §17200 and applicable statutes and laws of Plaintiff’s Home Forum.  
21 Plaintiff incorporates herein paragraphs 1 and 25-57, *supra*, as particularized evidence of the  
22 pattern of omission and concealment perpetrated by Pfizer against Plaintiff.

23           67. As a result of Pfizer’s violations of the UCL and applicable statutes and laws of  
24 Plaintiff’s Home Forum, Plaintiff is entitled to appropriate equitable relief and monetary relief  
25 in the form of restitution and interest. Plaintiff is also entitled to recover penalties, as well as an  
26 award of attorneys’ fees, costs, and expenses for prosecuting this action.

27           68. **WHEREFORE**, Plaintiff demands judgment against Defendant and seeks  
28 damages as detailed in the Global Prayer for Relief including: compensatory damages,

1 exemplary damages, and punitive damages, together with interest, the costs of suit and  
2 attorneys' fees, and such other and further relief as this Court deems just and proper.

3 **SECOND CAUSE OF ACTION**  
4 **Unfair and Deceptive Trade Practices**  
5 **(Fraud)**

6 69. Plaintiff adopts and incorporates all preceding paragraphs as if stated fully  
7 herein.

8 70. California Business & Professions Code Section 17200 ("Unfair Competition  
9 Law" or "UCL") and applicable statutes and laws of Plaintiff's Home Forum preclude unfair  
10 competition: *i.e.*, the employment of any unlawful, unfair or fraudulent business acts or  
11 practices; and, any unfair, deceptive, untrue or misleading advertising (Cal. Bus. & Prof. Code  
12 Section 17500). This prohibition extends to any act, omission, or conduct affecting the rights of  
13 consumers.

14 71. Pfizer has designed and continues to design, manufacture, market, sell, and place  
15 into the stream of commerce the Viagra purchased and used in California, Plaintiff's Home  
16 Forum, and throughout the United States. Pfizer has failed and continues to fail to disclose and  
17 conceal the serious safety hazard posed by the design of Viagra—it does not warn Plaintiff or  
18 his physicians of the increased risk of developing melanoma as a result of using Viagra, and  
19 should not be purchased or used for that purpose.

20 72. Pfizer has been and remains obligated to disclose this material safety hazard  
21 because reasonable consumers like Plaintiff expect Viagra to perform its only intended and  
22 reasonably expected function and purpose of allowing them to achieve and maintain an erection.  
23 In failing to disclose this critical safety hazard, known to Pfizer but not to reasonable consumers  
24 like Plaintiff or his physicians, Pfizer engaged in and continues to engage in fraudulent conduct  
25 by omission under Cal. Bus. & Prof. Code §17200 and applicable statutes and laws in Plaintiff's  
26 Home Forum. Plaintiff incorporates herein paragraphs 1 and 25-57, *supra*, as particularized  
27 evidence of the pattern of omission and concealment perpetrated by Pfizer against Plaintiff.

28 73. As a result of Pfizer's violations of the UCL and applicable statutes and laws in  
Plaintiff's Home Forum, Plaintiff is entitled to appropriate equitable relief and monetary relief

1 in the form of restitution and interest. Plaintiff is also entitled to recover penalties, as well as an  
2 award of attorneys' fees, costs, and expenses for prosecuting this action.

3 74. **WHEREFORE**, Plaintiff demands judgment against Defendant and seeks  
4 damages as detailed in the Global Prayer for Relief including: compensatory damages,  
5 exemplary damages, and punitive damages, together with interest, the costs of suit and  
6 attorneys' fees, and such other and further relief as this Court deems just and proper.

7 **THIRD CAUSE OF ACTION**  
8 **Unfair and Deceptive Trade Practices**  
9 **(Unlawfulness)**

10 75. Plaintiff adopts and incorporates all preceding paragraphs as if stated fully  
11 herein.

12 76. Pfizer's conduct is unlawful under the UCL because it violates Cal. Civ. Code §  
13 1750, *et seq.* (hereinafter "Consumer Legal Remedies Act" or "CLRA") and applicable statutes  
14 and laws in Plaintiff's Home Forum. Through omission and concealment, Pfizer has  
15 misrepresented and continues to misrepresent that Viagra: (a) has characteristics, uses or  
16 benefits that it does not have (Section 1770(a)(5)); and, (b) is of a particular standard, quality, or  
17 grade when they are of another (Section 1770(a)(7)). Plaintiff incorporates herein paragraphs 1  
18 and 25-57, *supra*, as particularized evidence of the pattern of misrepresentation by omission  
19 perpetrated by Pfizer against Plaintiff.

20 77. Were it not for Pfizer's unlawful conduct, Plaintiff would not have purchased  
21 Viagra. Instead, he would have purchased safe and reliable erectile dysfunction medication fit  
22 and safe for its intended purpose.

23 78. Plaintiff has and will continue to suffer injury in fact and lose money as a direct  
24 result of Pfizer's unfair competition in that he has had to undergo multiple surgeries and will  
25 continue to be required to undergo periodic skin checks to ensure against recurrence.

26 79. As a result of Pfizer's violations of the UCL and applicable statutes and laws in  
27 Plaintiff's Home Forum, Plaintiff is entitled to appropriate equitable relief and monetary relief  
28 in the form of restitution and interest. Plaintiff is also entitled to recover penalties, as well as an  
award of attorneys' fees, costs, and expenses for prosecuting this action.

1           80.     **WHEREFORE**, Plaintiff demands judgment against Defendant and seeks  
2 damages as detailed in the Global Prayer for Relief including: compensatory damages,  
3 exemplary damages, and punitive damages, together with interest, the costs of suit and  
4 attorneys' fees, and such other and further relief as this Court deems just and proper.

5                                   **FOURTH CAUSE OF ACTION**  
6                                   **(Strict Liability – Defective Design)**

7           81.     Plaintiff adopts and incorporates all preceding paragraphs as if stated fully  
8 herein.

9           82.     Defendant has a duty to provide adequate warnings and instructions for Viagra,  
10 to use reasonable care to design a product that is not unreasonably dangerous to users, and to  
11 adequately test its product.

12           83.     At all times relevant to this action, Defendant researched, designed, tested,  
13 manufactured, packaged, labeled, marketed, distributed, promoted, and sold Viagra, placing the  
14 drug into the stream of commerce.

15           84.     At all times relevant to this action, Viagra was designed, tested, inspected,  
16 manufactured, assembled, developed, labeled, sterilized, licensed, marketed, advertised,  
17 promoted, sold, packaged, supplied and/or distributed by Defendant in a condition that was  
18 defective and unreasonably dangerous to consumers, including the Plaintiff.

19           85.     Viagra is defective in its design and/or formulation in that it is not reasonably fit,  
20 suitable, or safe for its intended purpose and/or its foreseeable risks exceed the benefits  
21 associated with its design and formulation.

22           86.     Viagra was expected to reach, and did reach, users and/or consumers, including  
23 Plaintiff, without substantial change in the defective and unreasonably dangerous condition in  
24 which it was manufactured and sold.

25           87.     Plaintiff used Viagra as prescribed and in the foreseeable manner normally  
26 intended, recommended, promoted, and marketed by Defendant.

27           88.     Viagra was unreasonably dangerous in that, as designed, it failed to perform  
28 safely when used by ordinary consumers, including Plaintiff, when it was used as intended and  
in a reasonably foreseeable manner.

1           89.     Viagra was unreasonably dangerous and defective in design or formulation for  
2 its intended use in that, when it left the hands of the manufacturers and/or supplier, it posed a  
3 risk of serious injury which could have been reduced or avoided by the adoption of a feasible  
4 reasonable alternative design. There were safer alternative methods and designs for the like  
5 product.

6           90.     Viagra was insufficiently tested and caused harmful side effects that outweighed  
7 any potential utility.

8           91.     Viagra, as manufactured and supplied, was defective due to inadequate warnings,  
9 and/or inadequate clinical trials, testing and study, and inadequate reporting regarding the  
10 results of the clinical trials, testing and study.

11           92.     Viagra as manufactured and supplied by the Defendant was defective due to  
12 inadequate post-marketing warnings or instructions because, after Defendant knew or should  
13 have known of the risk of injuries from use and/or ingestion and acquired additional knowledge  
14 and information confirming the defective and dangerous nature of Viagra, Defendant failed to  
15 provide adequate warnings to the medical community and the consumers, to whom Defendant  
16 was directly marketing and advertising; and, further, Defendant continued to affirmatively  
17 promote Viagra as safe and effective.

18           93.     In light of the potential and actual risk of harm associated with the drug's use, a  
19 reasonable person who had actual knowledge of this potential and actual risk of harm would  
20 have concluded that Viagra should not have been marketed in that condition.

21           94.     As a direct and proximate cause of the Defendant's defective design of Viagra,  
22 including the lack of appropriate warnings, Plaintiff was prescribed and used the drug rather  
23 than alternative erectile dysfunction therapies with better and/or similar efficacy. As a result,  
24 Plaintiff has suffered significant pain, injury, harm, suffering, and economic damages incurred  
25 through cancer treatment necessitated by Viagra use.

26           95.     **WHEREFORE**, Plaintiff demands judgment against Defendant and seeks  
27 damages as detailed in the Global Prayer for Relief including: compensatory damages,  
28

1 exemplary damages, and punitive damages, together with interest, the costs of suit and  
2 attorneys' fees, and such other and further relief as this Court deems just and proper.

3 **FIFTH CAUSE OF ACTION**  
4 **(Strict Liability – Failure to Warn)**

5 96. Plaintiff adopts and incorporates all preceding paragraphs as if stated fully  
6 herein.

7 97. While designing and formulating Viagra, Pfizer discovered or should have  
8 discovered that the drug's mechanism of action, the inhibition of PDE5, also presented a  
9 significant risk of exacerbating melanoma.

10 98. Viagra was defective and unreasonably dangerous when it left the possession of  
11 the Defendant in that it contained warnings insufficient to alert consumers, including Plaintiff,  
12 of the dangerous risks and reactions associated with the subject product, including but not  
13 limited to the development and/or exacerbation of melanoma.

14 99. Information given by Defendant to the medical community and to consumers  
15 concerning the safety and efficacy of Viagra, especially the information contained in the  
16 advertising and promotional materials, did not accurately reflect the serious and potentially fatal  
17 side effects.

18 100. Had adequate warnings and instructions been provided, Plaintiff would not have  
19 been prescribed or taken Viagra, and would not have been at risk of the harmful side effects  
20 described herein.

21 101. Neither Plaintiff, nor Plaintiff's physicians knew, nor could they have learned  
22 through the exercise of reasonable care, the risks of serious injury and/or death associated with  
23 and/or caused by Viagra.

24 102. Defendant knew or had knowledge that the warnings that were given failed to  
25 properly warn of the increased risks of serious injury and/or death associated with and/or caused  
26 by Viagra.

27 103. Plaintiff, individually and through his prescribing physicians, reasonably relied  
28 upon the skill, superior knowledge, and judgment of the Defendant.





1 112. Had Defendant adequately tested relative efficacy of Viagra compared with other  
2 readily available, alternative erectile dysfunction therapies and disclosed those results to the  
3 medical community and the public, Plaintiff would not have purchased and used Viagra.

4 113. As a direct and proximate result of Pfizer's failure to adequately test Viagra,  
5 Plaintiff suffered significant pain, injury, suffering, and economic damages incurred through  
6 cancer treatment from melanoma caused by Viagra use.

7 114. **WHEREFORE**, Plaintiff demands judgment against Defendant and seeks  
8 damages as detailed in the Global Prayer for Relief including: compensatory damages,  
9 exemplary damages, and punitive damages, together with interest, the costs of suit and  
10 attorneys' fees, and such other and further relief as this Court deems just and proper.

11 **SEVENTH CAUSE OF ACTION**  
12 **(Negligence)**

13 115. Plaintiff adopts and incorporates all preceding paragraphs as if stated fully  
14 herein.

15 116. Defendant owed Plaintiff a duty to exercise reasonable care when designing,  
16 testing, manufacturing, labeling, marketing, advertising, promoting, distributing, and/or selling  
17 Viagra.

18 117. At all relevant times to this action, Defendant owed a duty to properly warn  
19 Plaintiff, physicians, consumers, and the public of the risks, dangers and adverse side effects of  
20 Viagra, including the increased risk of serious injury and death, when the drug was used as  
21 intended or in a way that Defendant could reasonably have anticipated.

22 118. Defendant breached its duty by failing to exercise ordinary care in the  
23 preparation, design, research, testing, development, manufacturing, inspection, labeling,  
24 marketing, promotion, advertising and selling of Viagra, as set forth below.

25 119. Defendant failed to exercise due care under the circumstances and therefore  
26 breached this duty in numerous ways, including the following:

- 27 a. failing to research and test Viagra properly and thoroughly before  
28 releasing the drug to the market;

- 1 b. failing to analyze properly and thoroughly the data resulting from the pre-
- 2 marketing tests of Viagra;
- 3 c. failing to report to the FDA, the medical community, and the general
- 4 public those data resulting from pre- and post-marketing tests of Viagra
- 5 which indicated serious risks associated with its use;
- 6 d. failing to conduct adequate post-market monitoring and surveillance of
- 7 Viagra;
- 8 e. failing to conduct adequate analysis of adverse event reports;
- 9 f. designing, manufacturing, marketing, promoting, advertising,
- 10 distributing, and selling Viagra to physicians and consumers, including
- 11 Plaintiff, without an adequate warning of the significant and dangerous
- 12 risks of Viagra and without proper instructions to avoid the harm that
- 13 could foreseeably occur as a result of using the drug;
- 14 g. failing to exercise due care when advertising and promoting Viagra;
- 15 h. negligently continuing to manufacture, market, advertise, and distribute
- 16 Viagra after Defendant knew or should have known of the risks of serious
- 17 injury and/or death associated with using the drug;
- 18 i. failing to use due care in the preparation and development of Viagra to
- 19 prevent the aforementioned risk of injuries to individuals when the drug
- 20 was ingested;
- 21 j. failing to use due care in the design of Viagra to prevent the
- 22 aforementioned risk of injuries to individuals when the drug was
- 23 ingested;
- 24 k. failing to conduct adequate pre-clinical testing and research to determine
- 25 the safety of Viagra;
- 26 l. failing to conduct adequate post-marketing surveillance and exposure
- 27 studies to determine the safety of Viagra, while Defendant knew or
- 28 should have known that post-marketing surveillance would be the only

1 means to determine the relative risk of Viagra for causing serious injury  
2 and/or death in the absence of clinical trials, and that such surveillance  
3 would be necessary for a due diligence program that would alert  
4 Defendant of the need to change the drug's warnings or to withdraw it  
5 from the market altogether;

6 m. failing to completely, accurately and in a timely fashion, disclose the  
7 results of the pre-marketing testing and post-marketing surveillance and  
8 testing to Plaintiff, Plaintiff's physicians, other consumers, the medical  
9 community, and the FDA;

10 n. failing to accompany Viagra with adequate and proper warnings  
11 regarding all possible adverse side effects, including serious injury (e.g.,  
12 development and/or exacerbation of melanoma) associated with the use  
13 of the same and instructions on ways to safely use Viagra to avoid injury;

14 o. failing to use due care in the manufacture, inspection, and labeling of  
15 Viagra to prevent the aforementioned risk of injuries to individuals who  
16 used the drug;

17 p. failing to use due care in the promotion of Viagra to prevent the  
18 aforementioned risk of injuries to individuals when the drug was  
19 ingested;

20 q. failing to use due care in the sale and marketing of Viagra to prevent the  
21 aforementioned risk of injuries to individuals when the drug was  
22 ingested;

23 r. failing to use due care in the selling of Viagra to prevent the  
24 aforementioned risk of injuries to individuals when the drug was  
25 ingested;

26 s. failing to provide adequate and accurate training and information to the  
27 sales representatives who sold the drug;

28 t. failing to provide adequate and accurate training and information to

1 healthcare providers for the appropriate use of Viagra;

- 2 u. failing to conduct or fund research into the development of medications  
3 of this type which would pose the least risk of causing serious injury and  
4 death as alleged herein, into the early detection of persons who might be  
5 most susceptible to such reactions, and into the development of better  
6 remedies and treatment for those who experience these tragic adverse  
7 reactions;
- 8 v. failing to educate healthcare providers, patients, and the public about the  
9 safest use of the drug;
- 10 w. failing to give patients and healthcare providers adequate information to  
11 weigh the risks of serious injury and/or death for a given patient; and
- 12 x. being otherwise reckless, careless and/or negligent.

13 120. Despite the fact that Defendant knew or should have known that Viagra  
14 increased the risk of serious injury and/or death, Defendant continued to promote and market  
15 Viagra to doctors and to consumers, including Plaintiff, when safer and more effective methods  
16 of treatment were available.

17 121. As a direct and proximate result of the negligence committed by Pfizer in testing  
18 and ultimately selling Viagra, Plaintiff suffered significant pain, injury, suffering, and economic  
19 damages incurred through cancer treatment from melanoma caused by Viagra use.

20 122. **WHEREFORE**, Plaintiff demands judgment against Defendant and seeks  
21 damages as detailed in the Global Prayer for Relief including: compensatory damages,  
22 exemplary damages, and punitive damages, together with interest, the costs of suit and  
23 attorneys' fees, and such other and further relief as this Court deems just and proper.

24 **EIGHTH CAUSE OF ACTION**  
25 **(Gross Negligence)**

26 123. Plaintiff adopts and incorporates all preceding paragraphs as if stated fully  
27 herein.

1           124. Defendant had a duty to exercise reasonable care in the warning about, design,  
2 testing, manufacture, marketing, labeling, sale, and/or distribution of Viagra, including a duty to  
3 ensure that Defendant's product, Viagra, did not cause users to suffer from unreasonable and  
4 dangerous side effects.

5           125. Defendant failed to exercise reasonable care in the warning about, design,  
6 testing, manufacture, marketing, labeling, sale, and/or distribution of Defendant's product,  
7 Viagra, in that Defendant knew or should have known that taking Viagra caused unreasonable  
8 and life-threatening injuries, as alleged herein.

9           126. Defendant was grossly negligent under the circumstances and breached its duty  
10 of care in numerous ways, including the following:

- 11           a. failing to test Viagra properly and thoroughly before releasing the drug to  
12           the market;
- 13           b. failing to analyze properly and thoroughly the data resulting from the pre-  
14           marketing tests of Viagra;
- 15           c. failing to report to the FDA, the medical community, and the general  
16           public those data resulting from pre- and post-marketing tests of Viagra  
17           which indicated risks associated with its use;
- 18           d. failing to conduct adequate post-market monitoring and surveillance of  
19           Viagra;
- 20           e. failing to conduct adequate analysis of adverse event reports;
- 21           f. designing, manufacturing, marketing, advertising, distributing, and  
22           selling Viagra to consumers, including Plaintiff, without an adequate  
23           warning of the significant and dangerous risks of Viagra and without  
24           proper instructions to avoid the harm which could foreseeably occur as a  
25           result of using the drug;
- 26           g. failing to exercise due care when advertising and promoting Viagra;

- 1 h. recklessly continuing to manufacture, market, advertise, and distribute
- 2 Viagra after Defendant knew or should have known of the risks of serious
- 3 injury and/or death associated with using the drug;
- 4 i. failing to use due care in the preparation and development of Viagra to
- 5 prevent the aforementioned risk of injuries to individuals when the drug
- 6 was ingested;
- 7 j. failing to use due care in the design of Viagra to prevent the
- 8 aforementioned risk of injuries to individuals when the drug was
- 9 ingested;
- 10 k. failing to conduct adequate pre-clinical testing and research to determine
- 11 the safety of Viagra;
- 12 l. failing to conduct adequate post-marketing surveillance and exposure
- 13 studies to determine the safety of Viagra, while Defendant knew or
- 14 should have known that post-marketing surveillance would be the only
- 15 means to determine the relative risk of Viagra for causing serious injury
- 16 and death as alleged herein in the absence of clinical trials, and that such
- 17 surveillance would be necessary for a due diligence program that would
- 18 alert Defendant to the need to change the drug's warnings or to withdraw
- 19 it from the market altogether;
- 20 m. failing to completely, accurately and in a timely fashion, disclose the
- 21 results of the pre-marketing testing and post-marketing surveillance and
- 22 testing to Plaintiff, her doctors, other consumers, the medical community,
- 23 and the FDA;
- 24 n. failing to accompany Viagra with proper warnings regarding all possible
- 25 adverse side effects associated with the use of the same;
- 26 o. failing to use due care in the manufacture, inspection, and labeling of
- 27 Viagra to prevent the aforementioned risk of injuries to individuals who
- 28 used the drug;

- 1 p. failing to use due care in the promotion of Viagra to prevent the
- 2 aforementioned risk of injuries to individuals when the drug was
- 3 ingested;
- 4 q. failing to use due care in the sale and marketing of Viagra to prevent the
- 5 aforementioned risk of injuries to individuals when the drug was
- 6 ingested;
- 7 r. failing to provide adequate and accurate training and information to the
- 8 sales representatives who sold the drug;
- 9 s. failing to provide adequate and accurate training and information to
- 10 healthcare providers for the appropriate use of Viagra;
- 11 t. failing to conduct or fund research into the development of medications
- 12 of this type which would pose the least risk of causing such serious injury
- 13 and death, as alleged herein, into the early detection of persons who
- 14 might be most susceptible to such reactions, and into the development of
- 15 better remedies and treatment for those who experience these tragic
- 16 adverse reactions;
- 17 u. failing to educate healthcare providers and the public about the safest use
- 18 of the drug;
- 19 v. failing to give healthcare providers adequate information to weigh the
- 20 risks of serious injury and/or death for a given patient; and
- 21 w. was otherwise grossly negligent.

22 127. Although Defendant knew, or recklessly disregarded, the fact that Defendant's  
23 product, Viagra, caused serious and potentially fatal side effects, Defendant continued to market  
24 Viagra to consumers, including Plaintiff, without disclosing these side effects including the  
25 risks of serious injury and/or death.

26 128. Defendant knew and/or consciously or recklessly disregarded the fact that  
27 consumers such as Plaintiff would suffer injury as a result of Defendant's failure to exercise  
28 reasonable care as described above.





- 1 c. Defendant failed to follow the “[s]pecific requirements on content and format  
2 of labeling for human prescription drugs” in violation of 21 C.F.R. § 201.57;  
3 and  
4 d. Defendant advertised and promoted Viagra in violation of 21 C.F.R. § 202.1;  
5 and  
6 e. Defendant violated 21 C.F.R. § 201.57(e) by failing to timely and adequately  
7 change the Viagra label to reflect the evidence of an association between  
8 Viagra and the development and/or exacerbation of melanoma suffered by  
9 Plaintiff.  
10

11 These statutes and regulations impose a standard of conduct designed to protect  
12 consumers of drugs, including Plaintiff. Defendant’s violations of these statutes and regulations  
13 constitute negligence per se.

14 135. As a direct and proximate result of Defendant’s statutory and regulatory  
15 violations, Plaintiff suffered significant pain, injury, suffering, and economic damages incurred  
16 through cancer treatment from melanoma caused by Viagra use.

17 136. **WHEREFORE**, Plaintiff demands judgment against Defendant and seeks  
18 damages as detailed in the Global Prayer for Relief including: compensatory damages,  
19 exemplary damages, and punitive damages, together with interest, the costs of suit and  
20 attorneys’ fees, and such other and further relief as this Court deems just and proper.

21 **TENTH CAUSE OF ACTION**  
22 **(Breach of Express Warranty)**

23 137. Plaintiff adopts and incorporates all preceding paragraphs as if stated fully  
24 herein.

25 138. At all times relevant hereto, Pfizer expressly represented and warranted to  
26 Plaintiff and his healthcare providers, by and through statements made by Pfizer or its  
27 authorized agents or sales representatives, orally and in publications, package inserts and other  
28

1 written materials intended for physicians, medical patients and the general public, that Viagra is  
2 safe, effective, and proper for its intended use.

3 139. Defendant breached expressed warranties with respect to Viagra in the following  
4 particulars:

5 a. Defendant represented through its labeling, advertising, marketing  
6 materials, seminar presentations, publications, notice letters, and  
7 regulatory submissions that Viagra was safe, and fraudulently withheld  
8 and concealed information about the substantial risks of serious injury  
9 and/or death associated with using Viagra;

10 b. Defendant represented that Viagra was as safe, and/or safer than other  
11 alternative medications and fraudulently concealed information that  
12 demonstrated that Viagra was not safer than alternatives available on the  
13 market; and

14 c. Defendant represented that Viagra was more efficacious than other  
15 alternative medications and fraudulently concealed information regarding  
16 the true efficacy of the drug.

17 140. Viagra does not conform to Defendant's express representations because its  
18 mechanism of action, the inhibition of the PDE5 enzyme, also increases the risk of the  
19 development and/or exacerbation of melanoma.

20 141. At all relevant times, Viagra did not perform as safely as an ordinary consumer  
21 would expect when used as intended or in a reasonably foreseeable manner.

22 142. Plaintiff, Plaintiff's physicians, other consumers, and the medical community  
23 relied upon Defendant's express warranties, resulting in Plaintiff's ingestion of the drug.

24 143. As a direct and proximate result of the breach of warranty committed by Pfizer,  
25 Plaintiff suffered significant pain, injury, suffering, and economic damages incurred through  
26 cancer treatment from melanoma caused by Viagra use.

27 144. **WHEREFORE**, Plaintiff demands judgment against Defendant and seeks  
28 damages as detailed in the Global Prayer for Relief including: compensatory damages,

1 exemplary damages, and punitive damages, together with interest, the costs of suit and  
2 attorneys' fees, and such other and further relief as this Court deems just and proper.

3 **ELEVENTH CAUSE OF ACTION**  
4 **(Breach of Implied Warranty)**

5 145. Plaintiff adopts and incorporates all preceding paragraphs as if stated fully  
6 herein.

7 146. At all relevant and material times, Defendant manufactured, distributed,  
8 advertised, promoted, and sold Viagra.

9 147. At all relevant times, Defendant intended that Viagra be used in the manner that  
10 Plaintiff in fact used it.

11 148. Defendant impliedly warranted Viagra to be of merchantable quality, safe and fit  
12 for the use for which Defendant intended it, and Plaintiff in fact used it.

13 149. Defendant was aware that consumers, including Plaintiff, would use Viagra to  
14 achieve and maintain an erection; which is to say that Plaintiff was a foreseeable user of  
15 Defendant's product Viagra.

16 150. Defendant knew, or had reason to know, that Plaintiff's physician would rely on  
17 Defendant's judgment and skill in providing Viagra for its intended use.

18 151. Plaintiff and his physician reasonably relied upon the skill and judgment of  
19 Defendant as to whether Viagra was of merchantable quality, safe and fit for its intended use.

20 152. The drug was expected to reach and did in fact did reach consumers, including  
21 Plaintiff, without substantial change in the condition in which it was manufactured and sold by  
22 Defendant.

23 153. Defendant breached various implied warranties with respect to Viagra including  
24 the following particulars:

- 25 a. Defendant represented through its labeling, advertising, marketing  
26 materials, seminar presentations, publications, notice letters, and  
27 regulatory submissions that Viagra was safe and fraudulently withheld  
28 and concealed information about the substantial risks of serious injury

1 and/or death associated with using Viagra;

2 b. Defendant represented that Viagra was as safe, and/or safer than other  
3 alternative medications and fraudulently concealed information that  
4 demonstrated that Viagra was not safer than alternatives available on the  
5 market; and

6 c. Defendant represented that Viagra was more efficacious than other  
7 alternative medications and fraudulently concealed information regarding  
8 the true efficacy of the drug.

9 154. In reliance upon Defendant's implied warranty, Plaintiff used Viagra as  
10 prescribed and in the foreseeable manner normally intended, recommended, promoted, and  
11 marketed by Defendant.

12 155. Viagra was neither safe for its intended use nor of merchantable quality, as had  
13 been implicitly warranted by Pfizer, in that Viagra's mechanism of action – the inhibition of  
14 PDE5 – inherently presented a significant increase in the user's risk of developing and/or  
15 exacerbating melanoma.

16 156. Defendant breached its implied warranty to Plaintiff in that Viagra is  
17 unreasonably dangerous, defective, and unfit for the ordinary purposes for which Viagra was  
18 used. It was not of merchantable quality, safe and fit for its intended use, or adequately tested.

19 157. As a direct and proximate result of the falsity of the warranties implicated by  
20 Pfizer's actions and omissions, Plaintiff suffered significant pain, injury, suffering, and  
21 economic damages incurred through cancer treatment from melanoma caused by Viagra use.

22 158. **WHEREFORE**, Plaintiff demands judgment against Defendant and seeks  
23 damages as detailed in the Global Prayer for Relief including: compensatory damages,  
24 exemplary damages, and punitive damages, together with interest, the costs of suit and  
25 attorneys' fees, and such other and further relief as this Court deems just and proper.

26 **TWELFTH CAUSE OF ACTION**  
27 **(Fraudulent Misrepresentation and Concealment)**  
28

1           159. Plaintiff adopts and incorporates all preceding paragraphs as if stated fully  
2 herein.

3           160. Defendant intentionally and fraudulently misrepresented to consumers and  
4 physicians, including Plaintiff, Plaintiff's physicians and the public in general, that Viagra had  
5 been tested and found to be safe, well-tolerated and/or more efficacious than alternative  
6 medications and/or methods of erectile dysfunction therapy and that Viagra's benefits  
7 outweighed its risks when used as instructed, when, in fact, Defendant knew, or should have  
8 known, and fraudulently concealed that Viagra is dangerous to patients and that the benefits of  
9 its use are far outweighed by the risks for Plaintiff and many others.

10           161. At all relevant times, Defendant knew of the use for which Viagra was intended  
11 and expressly and/or impliedly warranted its drug was of merchantable quality and safe and fit  
12 for such use.

13           162. Defendant had sole access to material facts concerning the dangers and  
14 unreasonable risks of Viagra.

15           163. Defendant's superior knowledge and expertise, its relationship of trust and  
16 confidence with doctors and the public, its specific knowledge regarding the risks and dangers  
17 of Viagra and its intentional dissemination of promotional and marketing information about  
18 Viagra for the purpose of maximizing its sales, each gave rise to the affirmative duty to  
19 meaningfully disclose and provide all material information about the risks and harms associated  
20 with the drug.

21           164. Defendant made false affirmative representations, omissions and/or fraudulently  
22 concealed material adverse information regarding the dangers, risks, safety, benefits, utility and  
23 effectiveness of Viagra in order to induce Plaintiff, Plaintiff's physicians, and the public in  
24 general to rely upon such representations and to use Viagra. By failing to disclose important  
25 safety and injury information and suppressing material facts about Viagra to Plaintiff, Plaintiff's  
26 physicians and the public in general, Defendant further led Plaintiff and Plaintiff's physicians to  
27 rely upon the safety of Viagra.

1           165. Defendant had a duty to disclose such information, arising from Defendant's  
2 actions of making, marketing, promoting, labeling, distributing and selling pharmaceutical  
3 products to Plaintiff and others.

4           166. Defendant's false representations and concealments were fraudulently made, in  
5 that Viagra in fact caused injury, was unsafe, and the benefits of its use were far outweighed by  
6 the risk associated with use thereof.

7           167. Defendant committed acts of intentional misrepresentation and intentional  
8 concealment by suppressing material facts relating to the dangers and substantial risks of  
9 serious injuries and/or death associated with, and caused by, the use of Viagra.

10           168. Defendant made such false representations, omissions and concealments with the  
11 intent or purpose that Plaintiff and Plaintiff's physicians would rely upon such representations,  
12 leading to the use of Viagra by Plaintiff.

13           169. Defendant made fraudulent affirmative misrepresentations and omissions and  
14 fraudulent concealments of material facts regarding the safety and effectiveness of Viagra and  
15 of the dangers and risks of injuries associated with Viagra, including:

16                   a. Defendant fraudulently represented through its labeling, advertising,  
17 marketing materials, seminar presentations, publications, notice letters,  
18 and regulatory submissions that Viagra had been adequately tested and  
19 found to be safe and effective for erectile dysfunction, and fraudulently  
20 concealed information about the substantial risks of serious injury and/or  
21 death associated with using Viagra; and

22                   b. Defendant fraudulently represented that Viagra was as safe and/or safer  
23 and/or more efficacious than other alternative erectile dysfunction  
24 therapies, and fraudulently concealed information that demonstrated that  
25 Viagra was not safer and/or more efficacious than alternatives available on  
26 the market.

27           170. Defendant knew, had reason to know, or should have known that these  
28 representations and actively concealed adverse information were false, and that Viagra had

1 defects and was unreasonably dangerous. Yet, Defendant willfully, wantonly, and recklessly  
2 disregarded its obligation to provide truthful representations regarding the safety and risk of  
3 Viagra to consumers, including Plaintiff, and to the medical community.

4 171. Defendant did not have adequate proof upon which to base such representations,  
5 and in fact, given Defendant's knowledge about Viagra's pharmacology and reported adverse  
6 events, Defendant knew or should have known that these representations, omissions and/or  
7 concealments were false and fraudulent. Specifically, Defendant knew of, possessed evidence  
8 and/or had reason to know that Viagra had defects and was unreasonably dangerous, causing the  
9 development and/or exacerbation of melanoma, as detailed herein.

10 172. Defendant's misrepresentations were made with the intent that physicians and  
11 patients, including Plaintiff, would rely upon them and were made with the intent of defrauding  
12 and deceiving Plaintiff, other consumers, and the medical community to induce and encourage  
13 the sale of Viagra.

14 173. Plaintiff, Plaintiff's physicians, and others, did rely upon and/or were induced by  
15 the misrepresentations, omissions and/or active concealment of the dangers of Viagra to the  
16 detriment of the Plaintiff.

17 174. Defendant's fraudulent representations and concealments evince its callous,  
18 reckless, willful, and depraved indifference to the health, safety, and welfare of consumers,  
19 including Plaintiff.

20 175. In selecting treatment, Plaintiff's physicians and Plaintiff relied on and were  
21 induced by Defendant's misrepresentations concerning the dangers of Viagra.

22 176. As detailed herein, Defendant made these fraudulent misrepresentations,  
23 omissions and concealments through statements and comments to the press, labeling,  
24 advertising, marketing and promotion materials, seminar presentations, publications, Dear  
25 Doctor letters and regulatory submissions.

26 177. Plaintiff and the treating medical community did not know that the  
27 representations, omissions, and/or concealments made by Defendant were false and were  
28 justified in reasonably relying upon Defendant's representations.





1 184. At all relevant times, Defendant designed, tested, manufactured, packaged,  
2 marketed, distributed, promoted, and sold Viagra.

3 185. At all relevant times, Defendant knew of the use for which Viagra was intended  
4 and expressly and/or impliedly warranted that the drug was of merchantable quality and safe  
5 and fit for such use.

6 186. Defendant's superior knowledge and expertise, its relationship of trust and  
7 confidence with doctors and the public, its specific knowledge regarding the risks and dangers  
8 of Viagra and its intentional dissemination of promotional and marketing information about  
9 Viagra for the purpose of maximizing its sales, each gave rise to the affirmative duty to disclose  
10 and provide all material information about the risks and harms associated with the drug.

11 187. Defendant recklessly, and/or negligently represented to Plaintiff, Plaintiff's  
12 physicians, and other persons and professionals whom Defendant knew would rely, that Viagra  
13 was safe to ingest and that the utility of this product outweighed any risk in use for their  
14 intended purposes.

15 188. Defendant recklessly and/or negligently failed to disclose to Plaintiff, and others,  
16 important safety and efficacy information, thereby suppressing material facts about the drug,  
17 while having a duty to disclose such information, which duty arose from its actions of making,  
18 marketing, promoting, distributing and selling pharmaceutical products to Plaintiff and others.

19 189. Defendant led Plaintiff to rely upon the safety of the product in its use.

20 190. The false representations of the Defendant were recklessly and/or negligently  
21 made in that Viagra in fact caused injury, was unsafe, and the benefits of its use were far  
22 outweighed by the risk associated with use thereof.

23 191. Defendant committed acts of reckless and/or negligent misrepresentation and  
24 reckless and/or negligent concealment by suppressing material facts relating to the dangers and  
25 injuries associated with, and caused by, the use of Viagra.

26 192. Defendant knew or should have known that its representations and/or omissions  
27 were false. Defendant made such false, negligent and/or reckless representations with the intent  
28

1 or purpose that Plaintiff and Plaintiff's physicians would rely upon such representations, leading  
2 to the use of Viagra by Plaintiff.

3 193. Defendant recklessly and/or negligently misrepresented, and/or omitted  
4 information with respect to Viagra in the following particulars:

5 a. Defendant represented through its labeling, advertising, marketing  
6 materials, seminar presentations, publications, notice letters, and  
7 regulatory submissions that Viagra was safe and fraudulently withheld  
8 and concealed information about the substantial risks of serious injury  
9 and/or death associated with using Viagra;

10 b. Defendant represented that Viagra was as safe and/or safer than other  
11 alternative erectile dysfunction therapies and fraudulently concealed  
12 information, which demonstrated that Viagra was not safer than  
13 alternatives available on the market; and

14 c. Defendant represented that Viagra was more efficacious than other  
15 alternative erectile dysfunction therapies and fraudulently concealed  
16 information, regarding the true efficacy of the drug.

17 194. Defendant made affirmative misrepresentations and recklessly and/or negligently  
18 omitted material adverse information regarding the safety and effectiveness of Viagra.

19 195. Defendant made these misrepresentations and/or omissions at a time when  
20 Defendant knew or had reason to know that Viagra had defects and was unreasonably  
21 dangerous and was not what Defendant had represented to the medical community, the FDA  
22 and the consuming public, including Plaintiff.

23 196. Defendant omitted, suppressed, and/or concealed material facts concerning the  
24 dangers and risk of injuries associated with the use of Viagra including, serious injury and  
25 death. Furthermore, Defendant was willfully blind to, ignored, downplayed, avoided, and/or  
26 otherwise understated the serious nature of the risks associated with the use of Viagra in order  
27 to increase sales.

1 197. Defendant's misrepresentations and/or omissions were undertaken by Defendant  
2 with an intent that doctors and patients, including Plaintiff, rely upon them.

3 198. Defendant's misrepresentations and/or omissions were undertaken with the intent  
4 of defrauding and/or deceiving Plaintiff, other consumers, and the medical community to induce  
5 and encourage the sale of Viagra.

6 199. Defendant's misrepresentations and/or omissions evinced the Defendant's  
7 callous, reckless, willful, and depraved indifference to the health, safety, and welfare of  
8 consumers, including Plaintiff.

9 200. Plaintiff's physician and Plaintiff relied on and were induced by Defendant's  
10 misrepresentations, omissions, and/or active concealment of the dangers of Viagra in selecting  
11 treatment.

12 201. Plaintiff and Plaintiff's physicians did not know that the representations made by  
13 Defendant were false and were justified in relying upon Defendant's representations.

14 202. Had Plaintiff been aware of the increased risk of side effects associated with  
15 Viagra and the relative efficacy of Viagra compared with other readily available alternative  
16 erectile dysfunction therapies, Plaintiff would not have taken Viagra.

17 203. As a direct and proximate consequence of Defendant's misrepresentations,  
18 Plaintiff sustained injuries and damages alleged herein including specifically those alleged  
19 herein.

20 204. Plaintiff relied on the misrepresentations made by Pfizer in purchasing and using  
21 Viagra.

22 205. Plaintiff's reliance on Pfizer's misrepresentations was justified because such  
23 misrepresentations were made by entities that were in a position to know of and disclose any  
24 potentially harmful information concerning the use of Viagra.

25 206. If Plaintiff had known of the information concealed by Pfizer regarding the  
26 melanoma-related risks posed by Viagra, Plaintiff would not have purchased and subsequently  
27 used Viagra.

28 207. As a direct and proximate result of the negligent misrepresentations by

1 Defendant, Plaintiff suffered significant pain, injury, suffering, and economic damages incurred  
2 through cancer treatment from melanoma caused by Viagra use.

3 208. **WHEREFORE**, Plaintiff demands judgment against Defendant and seeks  
4 damages as detailed in the Global Prayer for Relief including: compensatory damages,  
5 exemplary damages, and punitive damages, together with interest, the costs of suit and  
6 attorneys' fees, and such other and further relief as this Court deems just and proper.

7 **FOURTEENTH CAUSE OF ACTION**  
8 **(Fraud and Deceit)**

9 209. Plaintiff adopts and incorporates all preceding paragraphs as if stated fully  
10 herein.

11 210. At all times relevant hereto, Pfizer conducted a sales and marketing campaign to  
12 promote the sale of Viagra and willfully deceive Plaintiff, Plaintiff's healthcare providers, and  
13 the general public as to the benefits, health risks, and consequences of using Viagra.

14 211. While conducting its sales and marketing campaign, Pfizer knew that Viagra is  
15 neither safe nor fit for human consumption; that using Viagra is hazardous to health; and that  
16 Viagra has a propensity to cause serious injuries, such as those suffered by Plaintiff.

17 212. From the time the company first marketed and distributed Viagra until the  
18 present, Pfizer willfully deceived Plaintiff by concealing from him, his healthcare providers,  
19 and the general public the risks and dangers concerning the use of Viagra.

20 213. Pfizer intentionally concealed and suppressed the facts concerning Viagra's  
21 melanoma-related risks with the intent to defraud potential consumers, as Pfizer knew that  
22 healthcare providers would not prescribe Viagra, and consumers like Plaintiff would not use  
23 Viagra, if they were aware of the dangers posed by using Viagra.

24 214. As a direct and proximate result of Pfizer's fraudulent and deceitful conduct,  
25 Plaintiff suffered significant pain, injury, suffering, and economic damages incurred through  
26 cancer treatment from melanoma caused by Viagra use.

27 215. **WHEREFORE**, Plaintiff demands judgment against Defendant and seeks  
28 damages as detailed in the Global Prayer for Relief including: compensatory damages,

1 exemplary damages, and punitive damages, together with interest, the costs of suit and  
2 attorneys' fees, and such other and further relief as this Court deems just and proper.

3 **FIFTEENTH CAUSE OF ACTION**  
4 **(Willful, Wanton, and Malicious Conduct)**

5 216. Plaintiff adopts and incorporates all preceding paragraphs as if stated fully  
6 herein.

7 217. Pfizer directly or indirectly, maliciously and wantonly made, created,  
8 manufactured, designed, tested, labeled, supplied, packaged, distributed, promoted, marketed,  
9 advertised, warned, and/or sold Viagra.

10 218. Pfizer breached its duty and was wanton and malicious in its actions,  
11 misrepresentations, and omissions in that it:

- 12 a. failed to test Viagra properly and thoroughly before releasing the drug to  
13 the market;
- 14 b. failed to analyze properly and thoroughly the data resulting from the pre-  
15 marketing tests of Viagra;
- 16 c. failed to report to the FDA, the medical community, and the general  
17 public those data resulting from pre- and post-marketing tests of Viagra  
18 which indicated risks associated with its use;
- 19 d. failed to conduct adequate post-market monitoring and surveillance of  
20 Viagra;
- 21 e. failed to conduct adequate analysis of adverse event reports;
- 22 f. designed, manufactured, marketed, advertised, distributed, and sold  
23 Viagra to consumers, including Plaintiff, without an adequate warning of  
24 the significant and dangerous risks of Viagra and without proper  
25 instructions to avoid the harm which could foreseeably occur as a result  
26 of using the drug;
- 27 g. failed to exercise due care when advertising and promoting Viagra;
- 28

- 1 h. willfully and wantonly continued to manufacture, market, advertise, and
- 2 distribute Viagra after Defendant knew or should have known of the risks
- 3 of serious injury and/or death associated with using the drug;
- 4 i. willfully and wantonly failed to use due care in the preparation and
- 5 development of Viagra to prevent the aforementioned risk of injuries to
- 6 individuals when the drug was ingested;
- 7 j. willfully and wantonly failed to use due care in the design of Viagra to
- 8 prevent the aforementioned risk of injuries to individuals when the drug
- 9 was ingested;
- 10 k. failed to conduct adequate pre-clinical testing and research to determine
- 11 the safety of Viagra;
- 12 l. failed to conduct adequate post-marketing surveillance and exposure
- 13 studies to determine the safety of Viagra, while Defendant knew or
- 14 should have known that post-marketing surveillance would be the only
- 15 means to determine the relative risk of Viagra for causing such serious
- 16 injury and death as alleged herein in the absence of clinical trials, and that
- 17 such surveillance would be necessary for a due diligence program that
- 18 would alert Defendant to the need to change the drug's warnings or to
- 19 withdraw it from the market altogether;
- 20 m. failed to completely, accurately and in a timely fashion, disclose the
- 21 results of the pre-marketing testing and post-marketing surveillance and
- 22 testing to Plaintiff, Plaintiff's physicians, other consumers, the medical
- 23 community, and the FDA;
- 24 n. failed to accompany Viagra with proper warnings regarding all possible
- 25 adverse side effects associated with the use of the same;
- 26 o. willfully and wantonly failed to use due care in the manufacture,
- 27 inspection, and labeling of Viagra to prevent the aforementioned risk of
- 28 injuries to individuals who used the drug;

- 1 p. willfully and wantonly failed to use due care in the promotion of Viagra  
2 to prevent the aforementioned risk of injuries to individuals when the  
3 drug was ingested;
- 4 q. willfully and wantonly failed to use due care in the sale and marketing of  
5 Viagra to prevent the aforementioned risk of injuries to individuals when  
6 the drug was ingested;
- 7 r. willfully and wantonly failed to use due care in the selling of Viagra to  
8 prevent the aforementioned risk of injuries to individuals when the drug  
9 was ingested;
- 10 s. failed to provide adequate and accurate training and information to the  
11 sales representatives who sold the drug;
- 12 t. failed to provide adequate and accurate training and information to  
13 healthcare providers for the appropriate use of Viagra;
- 14 u. failed to conduct or fund research into the development of medications of  
15 this type which would pose the least risk of causing serious injury and  
16 death as alleged herein, into the early detection of persons who might be  
17 most susceptible to such reactions, and into the development of better  
18 remedies and treatment for those who experience these tragic adverse  
19 reactions;
- 20 v. failed to educate healthcare providers and the public about the safest use  
21 of the drug;
- 22 w. failed to give healthcare providers adequate information to weigh the  
23 risks of serious injury and/or death for a given patient; and
- 24 x. otherwise behaved willfully, wantonly, and maliciously.

25 219. Pfizer knew or should have known that Viagra was unreasonably dangerous and  
26 could cause serious injuries, including death.

27 220. As a direct and proximate result of the wanton and malicious acts and omissions  
28 of Pfizer, the Plaintiff sustained injuries and damages alleged herein.





1 who were prescribed the medication would experience and had already experienced severe  
2 physical, mental, and emotional injuries.

3 232. Pfizer, through its officers, directors, managers, and agents, knew that Viagra  
4 presented a substantial and unreasonable risk of harm to the public, including Plaintiff, and, as  
5 such, Pfizer unreasonably subjected consumers of said drugs to risk of injury or death from  
6 using Viagra.

7 233. Pfizer and its agents, officers, and directors intentionally proceeded with the  
8 manufacturing, sale, and distribution and marketing of Viagra knowing these actions would  
9 expose persons to serious danger in order to advance the company's market share and profits.

10 234. The acts, conduct, and omissions of Pfizer, as alleged throughout this Complaint,  
11 were willful and malicious.

12 235. Pfizer's unconscionable conduct warrants an award of exemplary and punitive  
13 damages against the company.

14 **GLOBAL PRAYER FOR RELIEF**

15 **WHEREFORE**, Plaintiff prays judgment against Pfizer as follows:

16 A. Declare, adjudge and decree the conduct of Defendant as alleged herein  
17 to be unlawful;

18 B. Actual, compensatory, punitive and/or exemplary damages in such  
19 amount to be determined at trial and as provided by applicable law;

20 C. Costs of suit, including reasonable attorneys' fees, and expenses as  
21 provided by law; and

22 D. Other, further, and different relief as the nature of the case may require or  
23 as may be determined to be just, equitable, and proper by this Court.

24 **DEMAND FOR JURY TRIAL**

25 Plaintiff Harvey Ellenthal demands a trial by jury.  
26  
27

28 Dated: August 11, 2016.

THE MICHAEL BRADY LYNCH FIRM

*/s/ Michael B. Lynch* \_\_\_\_\_

Michael B. Lynch  
THE MICHAEL BRADY LYNCH FIRM  
127 West Fairbanks Avenue., Suite 528  
Winter Park, Florida 32789  
Telephone: (877) 513-9517  
Facsimile: (321) 972-3568

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

**CIVIL COVER SHEET**

The JS 44 civil cover sheet and the information contained herein neither replace nor supplement the filing and service of pleadings or other papers as required by law, except as provided by local rules of court. This form, approved by the Judicial Conference of the United States in September 1974, is required for the use of the Clerk of Court for the purpose of initiating the civil docket sheet. (SEE INSTRUCTIONS ON NEXT PAGE OF THIS FORM.)

<p><b>I. (a) PLAINTIFFS</b> HARVEY ELLENTHAL</p> <p><b>(b)</b> County of Residence of First Listed Plaintiff <u>Broward County, FL</u> <i>(EXCEPT IN U.S. PLAINTIFF CASES)</i></p> <p><b>(c)</b> Attorneys <i>(Firm Name, Address, and Telephone Number)</i> The Michael Brady Lynch Firm 127 West Fairbanks Avenue., Suite 528 Winter Park, Florida 32789 (877) 513-9517</p>	<p><b>DEFENDANTS</b> PFIZER, INC.;</p> <p>County of Residence of First Listed Defendant <u>New York County, NY</u> <i>(IN U.S. PLAINTIFF CASES ONLY)</i></p> <p>NOTE: IN LAND CONDEMNATION CASES, USE THE LOCATION OF THE TRACT OF LAND INVOLVED.</p> <p>Attorneys <i>(If Known)</i></p>
---	--

<p><b>II. BASIS OF JURISDICTION</b> <i>(Place an "X" in One Box Only)</i></p> <p><input type="checkbox"/> 1 U.S. Government Plaintiff</p> <p><input type="checkbox"/> 2 U.S. Government Defendant</p> <p><input type="checkbox"/> 3 Federal Question <i>(U.S. Government Not a Party)</i></p> <p><input checked="" type="checkbox"/> 4 Diversity <i>(Indicate Citizenship of Parties in Item III)</i></p>	<p><b>III. CITIZENSHIP OF PRINCIPAL PARTIES</b> <i>(Place an "X" in One Box for Plaintiff and One Box for Defendant)</i></p> <table style="width:100%; border-collapse: collapse;"> <tr> <td style="width:33%;"></td> <td style="width:10%; text-align: center;"><b>PTF</b></td> <td style="width:10%; text-align: center;"><b>DEF</b></td> <td style="width:33%;"></td> <td style="width:10%; text-align: center;"><b>PTF</b></td> <td style="width:10%; text-align: center;"><b>DEF</b></td> </tr> <tr> <td>Citizen of This State</td> <td style="text-align: center;"><input type="checkbox"/> 1</td> <td style="text-align: center;"><input type="checkbox"/> 1</td> <td>Incorporated or Principal Place of Business In This State</td> <td style="text-align: center;"><input type="checkbox"/> 4</td> <td style="text-align: center;"><input type="checkbox"/> 4</td> </tr> <tr> <td>Citizen of Another State</td> <td style="text-align: center;"><input checked="" type="checkbox"/> 2</td> <td style="text-align: center;"><input type="checkbox"/> 2</td> <td>Incorporated and Principal Place of Business In Another State</td> <td style="text-align: center;"><input type="checkbox"/> 5</td> <td style="text-align: center;"><input checked="" type="checkbox"/> 5</td> </tr> <tr> <td>Citizen or Subject of a Foreign Country</td> <td style="text-align: center;"><input type="checkbox"/> 3</td> <td style="text-align: center;"><input type="checkbox"/> 3</td> <td>Foreign Nation</td> <td style="text-align: center;"><input type="checkbox"/> 6</td> <td style="text-align: center;"><input type="checkbox"/> 6</td> </tr> </table>		<b>PTF</b>	<b>DEF</b>		<b>PTF</b>	<b>DEF</b>	Citizen of This State	<input type="checkbox"/> 1	<input type="checkbox"/> 1	Incorporated or Principal Place of Business In This State	<input type="checkbox"/> 4	<input type="checkbox"/> 4	Citizen of Another State	<input checked="" type="checkbox"/> 2	<input type="checkbox"/> 2	Incorporated and Principal Place of Business In Another State	<input type="checkbox"/> 5	<input checked="" type="checkbox"/> 5	Citizen or Subject of a Foreign Country	<input type="checkbox"/> 3	<input type="checkbox"/> 3	Foreign Nation	<input type="checkbox"/> 6	<input type="checkbox"/> 6
	<b>PTF</b>	<b>DEF</b>		<b>PTF</b>	<b>DEF</b>																				
Citizen of This State	<input type="checkbox"/> 1	<input type="checkbox"/> 1	Incorporated or Principal Place of Business In This State	<input type="checkbox"/> 4	<input type="checkbox"/> 4																				
Citizen of Another State	<input checked="" type="checkbox"/> 2	<input type="checkbox"/> 2	Incorporated and Principal Place of Business In Another State	<input type="checkbox"/> 5	<input checked="" type="checkbox"/> 5																				
Citizen or Subject of a Foreign Country	<input type="checkbox"/> 3	<input type="checkbox"/> 3	Foreign Nation	<input type="checkbox"/> 6	<input type="checkbox"/> 6																				

**IV. NATURE OF SUIT** *(Place an "X" in One Box Only)*

CONTRACT	TORTS	FORFEITURE/PENALTY	BANKRUPTCY	OTHER STATUTES		
<input type="checkbox"/> 110 Insurance <input type="checkbox"/> 120 Marine <input type="checkbox"/> 130 Miller Act <input type="checkbox"/> 140 Negotiable Instrument <input type="checkbox"/> 150 Recovery of Overpayment & Enforcement of Judgment <input type="checkbox"/> 151 Medicare Act <input type="checkbox"/> 152 Recovery of Defaulted Student Loans <i>(Excludes Veterans)</i> <input type="checkbox"/> 153 Recovery of Overpayment of Veteran's Benefits <input type="checkbox"/> 160 Stockholders' Suits <input type="checkbox"/> 190 Other Contract <input type="checkbox"/> 195 Contract Product Liability <input type="checkbox"/> 196 Franchise	<p><b>PERSONAL INJURY</b></p> <input type="checkbox"/> 310 Airplane <input type="checkbox"/> 315 Airplane Product Liability <input type="checkbox"/> 320 Assault, Libel & Slander <input type="checkbox"/> 330 Federal Employers' Liability <input type="checkbox"/> 340 Marine <input type="checkbox"/> 345 Marine Product Liability <input type="checkbox"/> 350 Motor Vehicle <input type="checkbox"/> 355 Motor Vehicle Product Liability <input type="checkbox"/> 360 Other Personal Injury <input type="checkbox"/> 362 Personal Injury - Medical Malpractice	<p><b>PERSONAL INJURY</b></p> <input type="checkbox"/> 365 Personal Injury - Product Liability <input checked="" type="checkbox"/> 367 Health Care/Pharmaceutical Personal Injury Product Liability <input type="checkbox"/> 368 Asbestos Personal Injury Product Liability <p><b>PERSONAL PROPERTY</b></p> <input type="checkbox"/> 370 Other Fraud <input type="checkbox"/> 371 Truth in Lending <input type="checkbox"/> 380 Other Personal Property Damage <input type="checkbox"/> 385 Property Damage Product Liability	<input type="checkbox"/> 625 Drug Related Seizure of Property 21 USC 881 <input type="checkbox"/> 690 Other	<input type="checkbox"/> 422 Appeal 28 USC 158 <input type="checkbox"/> 423 Withdrawal 28 USC 157	<input type="checkbox"/> 375 False Claims Act <input type="checkbox"/> 400 State Reapportionment <input type="checkbox"/> 410 Antitrust <input type="checkbox"/> 430 Banks and Banking <input type="checkbox"/> 450 Commerce <input type="checkbox"/> 460 Deportation <input type="checkbox"/> 470 Racketeer Influenced and Corrupt Organizations <input type="checkbox"/> 480 Consumer Credit <input type="checkbox"/> 490 Cable/Sat TV <input type="checkbox"/> 850 Securities/Commodities/Exchange <input type="checkbox"/> 890 Other Statutory Actions <input type="checkbox"/> 891 Agricultural Acts <input type="checkbox"/> 893 Environmental Matters <input type="checkbox"/> 895 Freedom of Information Act <input type="checkbox"/> 896 Arbitration <input type="checkbox"/> 899 Administrative Procedure Act/Review or Appeal of Agency Decision <input type="checkbox"/> 950 Constitutionality of State Statutes	
<p><b>REAL PROPERTY</b></p> <input type="checkbox"/> 210 Land Condemnation <input type="checkbox"/> 220 Foreclosure <input type="checkbox"/> 230 Rent Lease & Ejectment <input type="checkbox"/> 240 Torts to Land <input type="checkbox"/> 245 Tort Product Liability <input type="checkbox"/> 290 All Other Real Property	<p><b>CIVIL RIGHTS</b></p> <input type="checkbox"/> 440 Other Civil Rights <input type="checkbox"/> 441 Voting <input type="checkbox"/> 442 Employment <input type="checkbox"/> 443 Housing/Accommodations <input type="checkbox"/> 445 Amer. w/Disabilities Employment <input type="checkbox"/> 446 Amer. w/Disabilities Other <input type="checkbox"/> 448 Education	<p><b>PRISONER PETITIONS</b></p> <p><b>Habeas Corpus:</b></p> <input type="checkbox"/> 463 Alien Detainee <input type="checkbox"/> 510 Motions to Vacate Sentence <input type="checkbox"/> 530 General <input type="checkbox"/> 535 Death Penalty	<p><b>LABOR</b></p> <input type="checkbox"/> 710 Fair Labor Standards Act <input type="checkbox"/> 720 Labor/Management Relations <input type="checkbox"/> 740 Railway Labor Act <input type="checkbox"/> 751 Family and Medical Leave Act <input type="checkbox"/> 790 Other Labor Litigation <input type="checkbox"/> 791 Employee Retirement Income Security Act	<p><b>SOCIAL SECURITY</b></p> <input type="checkbox"/> 861 HIA (1395ff) <input type="checkbox"/> 862 Black Lung (923) <input type="checkbox"/> 863 DIWC/DIWW (405(g)) <input type="checkbox"/> 864 SSID Title XVI <input type="checkbox"/> 865 RSI (405(g))	<p><b>PROPERTY RIGHTS</b></p> <input type="checkbox"/> 820 Copyrights <input type="checkbox"/> 830 Patent <input type="checkbox"/> 840 Trademark	<p><b>FEDERAL TAX SUITS</b></p> <input type="checkbox"/> 870 Taxes (U.S. Plaintiff or Defendant) <input type="checkbox"/> 871 IRS—Third Party 26 USC 7609

**V. ORIGIN** *(Place an "X" in One Box Only)*

1 Original Proceeding     2 Removed from State Court     3 Remanded from Appellate Court     4 Reinstated or Reopened     5 Transferred from Another District *(specify)*     6 Multidistrict Litigation

**VI. CAUSE OF ACTION**

Cite the U.S. Civil Statute under which you are filing *(Do not cite jurisdictional statutes unless diversity):*  
28 U.S.C. 1332

Brief description of cause:

**VII. REQUESTED IN COMPLAINT:**     CHECK IF THIS IS A CLASS ACTION UNDER RULE 23, F.R.Cv.P.    **DEMAND \$**    CHECK YES only if demanded in complaint: **JURY DEMAND:**     Yes     No

**VIII. RELATED CASE(S) IF ANY** *(See instructions):*    JUDGE Richard Seeborg    DOCKET NUMBER MDL 2961

**IX. DIVISIONAL ASSIGNMENT (Civil L.R. 3-2)** *(Place an "X" in One Box Only)*     **SAN FRANCISCO/OAKLAND**     **SAN JOSE**     **EUREKA**

DATE 8/11/2016    SIGNATURE OF ATTORNEY OF RECORD /s/ Michael B. Lynch

## INSTRUCTIONS FOR ATTORNEYS COMPLETING CIVIL COVER SHEET FORM JS 44

## Authority For Civil Cover Sheet

The JS 44 civil cover sheet and the information contained herein neither replaces nor supplements the filings and service of pleading or other papers as required by law, except as provided by local rules of court. This form, approved by the Judicial Conference of the United States in September 1974, is required for the use of the Clerk of Court for the purpose of initiating the civil docket sheet. Consequently, a civil cover sheet is submitted to the Clerk of Court for each civil complaint filed. The attorney filing a case should complete the form as follows:

- I. (a) Plaintiffs-Defendants.** Enter names (last, first, middle initial) of plaintiff and defendant. If the plaintiff or defendant is a government agency, use only the full name or standard abbreviations. If the plaintiff or defendant is an official within a government agency, identify first the agency and then the official, giving both name and title.
- (b) County of Residence.** For each civil case filed, except U.S. plaintiff cases, enter the name of the county where the first listed plaintiff resides at the time of filing. In U.S. plaintiff cases, enter the name of the county in which the first listed defendant resides at the time of filing. (NOTE: In land condemnation cases, the county of residence of the "defendant" is the location of the tract of land involved.)
- (c) Attorneys.** Enter the firm name, address, telephone number, and attorney of record. If there are several attorneys, list them on an attachment, noting in this section "(see attachment)".
- II. Jurisdiction.** The basis of jurisdiction is set forth under Rule 8(a), F.R.Cv.P., which requires that jurisdictions be shown in pleadings. Place an "X" in one of the boxes. If there is more than one basis of jurisdiction, precedence is given in the order shown below.  
 United States plaintiff. (1) Jurisdiction based on 28 U.S.C. 1345 and 1348. Suits by agencies and officers of the United States are included here.  
 United States defendant. (2) When the plaintiff is suing the United States, its officers or agencies, place an "X" in this box.  
 Federal question. (3) This refers to suits under 28 U.S.C. 1331, where jurisdiction arises under the Constitution of the United States, an amendment to the Constitution, an act of Congress or a treaty of the United States. In cases where the U.S. is a party, the U.S. plaintiff or defendant code takes precedence, and box 1 or 2 should be marked.  
 Diversity of citizenship. (4) This refers to suits under 28 U.S.C. 1332, where parties are citizens of different states. When Box 4 is checked, the citizenship of the different parties must be checked. (See Section III below; **NOTE: federal question actions take precedence over diversity cases.**)
- III. Residence (citizenship) of Principal Parties.** This section of the JS 44 is to be completed if diversity of citizenship was indicated above. Mark this section for each principal party.
- IV. Nature of Suit.** Place an "X" in the appropriate box. If the nature of suit cannot be determined, be sure the cause of action, in Section VI below, is sufficient to enable the deputy clerk or the statistical clerk(s) in the Administrative Office to determine the nature of suit. If the cause fits more than one nature of suit, select the most definitive.
- V. Origin.** Place an "X" in one of the six boxes.  
 Original Proceedings. (1) Cases which originate in the United States district courts.  
 Removed from State Court. (2) Proceedings initiated in state courts may be removed to the district courts under Title 28 U.S.C., Section 1441. When the petition for removal is granted, check this box.  
 Remanded from Appellate Court. (3) Check this box for cases remanded to the district court for further action. Use the date of remand as the filing date.  
 Reinstated or Reopened. (4) Check this box for cases reinstated or reopened in the district court. Use the reopening date as the filing date.  
 Transferred from Another District. (5) For cases transferred under Title 28 U.S.C. Section 1404(a). Do not use this for within district transfers or multidistrict litigation transfers.  
 Multidistrict Litigation. (6) Check this box when a multidistrict case is transferred into the district under authority of Title 28 U.S.C. Section 1407. When this box is checked, do not check (5) above.
- VI. Cause of Action.** Report the civil statute directly related to the cause of action and give a brief description of the cause. **Do not cite jurisdictional statutes unless diversity.** Example: U.S. Civil Statute: 47 USC 553 Brief Description: Unauthorized reception of cable service
- VII. Requested in Complaint.** Class Action. Place an "X" in this box if you are filing a class action under Rule 23, F.R.Cv.P.  
 Demand. In this space enter the actual dollar amount being demanded or indicate other demand, such as a preliminary injunction.  
 Jury Demand. Check the appropriate box to indicate whether or not a jury is being demanded.
- VIII. Related Cases.** This section of the JS 44 is used to reference related pending cases, if any. If there are related pending cases, insert the docket numbers and the corresponding judge names for such cases.

**Date and Attorney Signature.** Date and sign the civil cover sheet.